The metalloproteinase-mediated pathway is essential for generation of soluble HLA class I proteins by activated cells in vitro: proposed mechanism for soluble HLA release in transplant rejection.
We and others have found donor-derived soluble beta2m-associated HLA class I proteins (sHLA/beta2m) in the serum of allograft recipients with acute and chronic rejection. Whether appearance of sHLA/beta2m and upregulated expression of donor cell-bound HLA/beta2m during allograft rejection are related events is unknown. Activation-induced upregulation of in vitro HLA/beta2m expression correlates with the surface expression of another form of HLA class I, namely beta2m-free HLA heavy chains (beta2m-free HC). We have shown that beta2m-free HC, but not beta2m-associated HC, are then cleaved by a specific membrane-bound metalloproteinase and released into supernatants as soluble 36 kDa proteins. We show now that activated peripheral blood lymphocytes produce predominantly the 36 kDa form of sHLA proteins which is present in supernatants as both beta2m-free HC and sHLA/beta2m. Importantly, the metalloprotease inhibitor BB-94 blocked not only the release of soluble beta2m-free HC, but also the appearance of sHLA/beta2m in cell supernatants. Low levels of 36 kDa beta2m-free HC were also present in human plasma of healthy donors. These data suggest an important role for the HLA class I-specific metalloproteinase in vivo in healthy individuals and during allograft rejection in the generation of soluble beta2m-free and beta2m-associated HLA proteins.
DeVito-Haynes
L D
LD
University of Wisconsin, Madison 53792, USA. haynes@surgery.wisc.edu
Demaria
S
S
Bushkin
Y
Y
Burlingham
W J
WJ
D002474:Cell-Free System; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D006084:Graft Rejection / Q000201:enzymology / Q000276:immunology*; D006680:HLA Antigens / Q000096:biosynthesis*; D015395:Histocompatibility Antigens Class I / Q000096:biosynthesis*; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism*; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000502:physiology*; D008970:Molecular Weight; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000494:pharmacology; D011043:Pokeweed Mitogens / Q000494:pharmacology; D012995:Solubility; D013876:Thiophenes / Q000494:pharmacology; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000378:metabolism
D004791:Enzyme Inhibitors; D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D011043:Pokeweed Mitogens; D013876:Thiophenes; D001613:beta 2-Microglobulin; D010649:Phenylalanine; C080985:batimastat; D008666:Metalloendopeptidases